Living donor liver transplantations in HIV- and hepatitis C virus-coinfected hemophiliacs: Experience in a single center

Transplantation

Volumn 91, Issue 11, 2011, Pages 1261-1264

  Tsukada, Kunihisa ^a,b   Sugawara, Yasuhiko ^c   Kaneko, Junichi ^c   Tamura, Sumihito ^c   Tachikawa, Natsuo ^b,d   Morisawa, Yuji ^a,e   Okugawa, Shu ^a   Kikuchi, Yoshimi ^b   Oka, Shinichi ^b   Kimura, Satoshi ^a,b,f   Yatomi, Yutaka ^c   Makuuchi, Masatoshi ^g   Kokudo, Norihiro ^c   Koike, Kazuhiko ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^e JICHI MEDICAL UNIVERSITY   (Japan)

^f TOKYO TEISHIN HOSPITAL   (Japan)

^g Japanese Red Central Blood Center   (Japan)

Author keywords

HAART; Hepatitis C virus; HIV; Living donor liver transplantation

Indexed keywords

ANTIRETROVIRUS AGENT; GANCICLOVIR; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PEGINTERFERON; RIBAVIRIN; STEROID; VALGANCICLOVIR;

ADULT; ARTICLE; BLEEDING; CAUSE OF DEATH; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CYTOMEGALOVIRUS INFECTION; FATALITY; FOLLOW UP; GENOTYPE; GRAFT FAILURE; GRAFT REJECTION; HEMOPHILIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LIVING DONOR; MALE; MIXED INFECTION; PRIORITY JOURNAL; RECURRENT DISEASE; SURVIVAL RATE;

ADULT; BLOOD COAGULATION; CD4 LYMPHOCYTE COUNT; HEMOPHILIA A; HEPATITIS C; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; LIVER TRANSPLANTATION; LIVING DONORS; MALE; SURVIVAL RATE;

EID: 79958271560     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3182193cf3     Document Type: Article

References (34)

1. Mocroft A, Ledergerber B, Katlama C, et al. Decline in the AIDS and death rates in the EuroSIDA study: An observational study. Lancet 2003; 362: 22.
2. Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: Changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr 2006; 43: 27.
3. Weber R, Sabin CA, Friis-Moller N, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: The D:A:D study. Arch Intern Med 2006; 166: 1632.
4. Koike K, Tsukada K, Yotsuyanagi H, et al. Prevalence of coinfection with human immunodeficiency virus and hepatitis C virus in Japan. Hepatol Res 2007; 37: 2.
5. Mohsen AH, Easterbrook PJ, Taylor C, et al. Impact of human immunodeficiency virus (HIV) infection on the progression of liver fibrosis in hepatitis C virus infected patients. Gut 2003; 52: 1035.
6. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451.
7. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIVinfected patients. N Engl J Med 2004; 351: 438.
8. Yotsuyanagi H, Kikuchi Y, Tsukada K, et al. Chronic hepatitis C in patients co-infected with human immunodeficiency virus in Japan: A retrospective multicenter analysis. Hepatol Res 2009; 39: 657.
9. Tatsunami S, Fukutake K, Taki M, et al. Observed decline in the rate of death among Japanese hemophiliacs infected with HIV-1. Int J Hematol 2000; 72: 256.
10. Tatsunami S, Taki M, Shirahata A, et al. Increasing incidence of critical liver disease among causes of death in Japanese hemophiliacs with HIV-1. Acta Haematol 2004; 111: 181.
11. Tzakis AG, Cooper MH, Dummer JS, et al. Transplantation in HIV+patients. Transplantation 1990; 49: 354.
12. Gordon FH, Mistry PK, Sabin CA, et al. Outcome of orthotopic liver transplantation in patients with haemophilia. Gut 1998; 42: 744.
13. Moreno-Cuerda VJ, Morales-Conejo M. Liver transplantation in patients with HIV infection. Gastroenterol Hepatol 2005; 28: 258. (Pubitemid 40592587)
14. Neff GW, Bonham A, Tzakis AG, et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl 2003; 9: 239.
15. Norris S, Taylor C, Muiesan P, et al. Outcomes of liver transplantation in HIV-infected individuals: The impact of HCV and HBV infection. Liver Transpl 2004; 10: 1271.
16. Fung J, Eghtesad B, Patel-Tom K, et al. Liver transplantation in patients with HIV infection. Liver Transpl 2004; 10: S39.
17. Vogel M, Voigt E, Schafer N, et al. Orthotopic liver transplantation in human immunodeficiency virus (HIV)-positive patients: Outcome of 7 patients from the Bonn cohort. Liver Transpl 2005; 11: 1515.
18. Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26: 273.
19. Mindikoglu AL, Regev A, Magder LS. Impact of human immunodeficiency virus on survival after liver transplantation: Analysis of United Network for Organ Sharing database. Transplantation 2008; 85: 359.
20. Tateo M, Roque-Afonso AM, Antonini TM, et al. Long-term follow-up of liver transplanted HIV/hepatitis B virus coinfected patients: Perfect control of hepatitis B virus replication and absence of mitochondrial toxicity. AIDS 2009; 23: 1069.
21. Testillano M, Fernandez JR, Suarez MJ, et al. Survival and hepatitis C virus recurrence after liver transplantation in HIV- and hepatitis C virus-coinfected patients: Experience in a single center. Transplant Proc 2009; 41: 1041.
22. Sugawara Y, Ohkubo T, Makuuchi M, et al. Living-donor liver transplantation in an HIV-positive patient with hemophilia. Transplantation 2002; 74: 1655.
23. Cortes J, Thomas D, Rios A, et al. Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia. Cancer 2002; 94: 1492.
24. Troppmann C, Rossaro L, Perez RV, et al. Early, rapidly progressive cholestatic hepatitis C reinfection and graft loss after adult living donor liver transplantation. Am J Transplant 2003; 3: 239.
25. Gaglio PJ, Malireddy S, Levitt BS, et al. Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. Liver Transpl 2003; 9: 1028.
26. Kornberg A, Kupper B, Tannapfel A, et al. Antiviral maintenance treatment with interferon and ribavirin for recurrent hepatitis C after liver transplantation: Pilot study. J Gastroenterol Hepatol 2007; 22: 2135.
27. Sulkowski MS. Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors. Clin Infect Dis 2004; 38: S90.
28. Tricot L, Teicher E, Peytavin G, et al. Safety and efficacy of raltegravir in HIV-infected transplant patients cotreated with immunosuppressive drugs. Am J Transplant 2009; 9: 1946.
29. Teicher E, Abbara C, Duclos-Vallee JC, et al. Enfuvirtide: A safe and effective antiretroviral agent for human immunodeficiency virusinfected patients shortly after liver transplantation. Liver Transpl 2009; 15: 133.
30. Kowalski RJ, Post DR, Mannon RB, et al. Assessing relative risks of infection and rejection: A meta-analysis using an immune function assay. Transplantation 2006; 82: 663.
31. Sugawara Y, Makuuchi M, Kaneko J, et al. Correlation between optimal tacrolimus doses and the graft weight in living donor liver transplantation. Clin Transplant 2002; 16: 102.
32. Kishi Y, Sugawara Y, Akamatsu N, et al. Splenectomy and preemptive interferon therapy for hepatitis C patients after living-donor liver transplantation. Clin Transplant 2005; 19: 769.
33. Sugawara Y, Makuuchi M, Matsui Y, et al. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308.
34. Koetz AC, Delbruck R, Furtwangler A, et al. Cytomegalovirus pp65 antigen-guided preemptive therapy with ganciclovir in solid organ transplant recipients: A prospective, double-blind, placebo-controlled study. Transplantation 2001; 72: 1325.